Systems biology of glutamine utilization in melanoma

黑色素瘤中谷氨酰胺利用的系统生物学

• 批准号: 8624405
• 负责人: Jeffrey W Smith
• 金额: $ 25.45万
• 依托单位: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8624405
• 关键词: Accounting; Address; American Cancer Society; BRAF gene; Biological Assay; Biological Markers; Carbon; Cell Line; Cells; Cellular biology; Cessation of life; Citric Acid Cycle; Development; Diagnostic; Disease; Drug Targeting; Energy-Generating Resources; Engineering; Enzymes; Gene Expression; Gene Silencing; Gene Targeting; Genetic Suppression; Glutamates; Glutaminase; Glutamine; Growth; Health; Human; In Vitro; Malignant Neoplasms; Medical; Melanoma Cell; Metabolic; Metabolic Pathway; Metabolism; Modeling; Monitor; Mus; Mutate; Mutation; Neoplasm Metastasis; Nitrogen; Oncogenes; Oncogenic; Output; Pathway interactions; Patients; Physiological; Physiology; Primary Neoplasm; Production; Research; Research Personnel; Resistance; Role; Side; Signal Pathway; Skin Cancer; Source; Staging; Systems Biology; Techniques; Testing; Therapeutic; Therapeutic Agents; Validation; Xenograft Model; Xenograft procedure; addiction; base; cell type; deprivation; feeding; in vivo; insight; interest; melanoma; metabolomics; mouse model; new therapeutic target; novel; novel therapeutics; overexpression; stable isotope; therapeutic development; therapeutic target; translational study; tumor; tumor growth; tumor progression; tumor xenograft; tumorigenesis

DESCRIPTION (provided by applicant): Development of new therapies against melanoma, a nearly incurable disease if allowed to progress to the deadly metastatic stage, is a well-recognized medical need. As in all other cancers, tumorigenesis and tumor progression in melanoma is accompanied by substantial rewiring of central carbon metabolism opening unexplored opportunities for diagnostics and treatment. Recent studies of the investigators of this application implicated a substantially enhanced utilization of glutamine as an essential anaplerotic source of carbon and energy and a potential therapeutic target in human melanoma cell lines. The preliminary results of these studies led to the specific hypothesis about the critial importance of the cataplerotic exit of glutamine- originating carbon units from the tricarboxylic acid cycle, which may provide unique targeting opportunities. The proposed studies will address this hypothesis using an established integrative approach, which combines multifaceted metabolic analyses, including stable-isotope tracing, with genetic suppression of selected target enzymes over a panel of representative human melanoma lines followed by testing and validation of main finding in mouse xenograft models. In addition to gaining fundamental mechanistic insights, anticipated deliverables of the project would include validated biomarkers (signature metabolites and/or fluxes) and potential target enzymes. The proposed research plan includes two major specific aims featuring in vitro and in vivo studies: (I) to elucidate mechanisms and identify potential diagnostic and therapeutic targets involved in the key aspects of glutamine metabolism in a range of melanoma cell lines by a synergistic combination of techniques including targeted metabolomics, physiology and cell biology; (II) to validate the key aspects of glutamine metabolism, biomarkers and tentatively identified targets in the xenograft mouse models of primary melanoma tumors and metastases. If successfully accomplished, this project would provide a strong starting point for advanced translational studies and therapeutic developments

描述（由申请人提供）：开发针对黑色素瘤的新疗法是一种公认的医学需求，黑色素瘤是一种几乎无法治愈的疾病，如果允许其进展到致命的转移阶段。与所有其他癌症一样，黑色素瘤的肿瘤发生和肿瘤进展伴随着中心碳代谢的大量重新布线，为诊断和治疗开辟了未探索的机会。本申请的研究者的最近研究暗示了谷氨酰胺作为碳和能量的基本回补来源以及人黑素瘤细胞系中的潜在治疗靶点的显著增强的利用。这些研究的初步结果导致了关于谷氨酰胺来源的碳单元从三羧酸循环中退出的关键重要性的特定假设，这可能提供独特的靶向机会。拟议的研究将使用一种已建立的综合方法来解决这一假设，该方法将多方面的代谢分析（包括稳定同位素示踪）与一组代表性人类黑色素瘤细胞系中选定靶酶的遗传抑制相结合，然后在小鼠异种移植模型中测试和验证主要发现。除了获得基本的机制见解外，该项目的预期成果还包括经验证的生物标志物（特征代谢物和/或通量）和潜在的靶酶。拟议的研究计划包括两个主要的具体目标，包括体外和体内研究：（I）通过靶向代谢组学，生理学和细胞生物学等技术的协同组合，阐明一系列黑色素瘤细胞系中谷氨酰胺代谢关键方面的机制并确定潜在的诊断和治疗靶点;（II）验证原发性黑色素瘤肿瘤和转移瘤异种移植小鼠模型中谷氨酰胺代谢、生物标志物和暂时确定的靶点的关键方面。如果成功完成，该项目将为高级转化研究和治疗开发提供一个强有力的起点